Plus Therapeutics Inc - Asset Resilience Ratio
Plus Therapeutics Inc (PSTV) has an Asset Resilience Ratio of 44.34% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PSTV current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Plus Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PSTV total assets.
Liquid Assets Composition Over Time
This chart breaks down Plus Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read PSTV current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.22 Million | 44.34% |
| Total Liquid Assets | $6.22 Million | 44.34% |
Asset Resilience Insights
- Very High Liquidity: Plus Therapeutics Inc maintains exceptional liquid asset reserves at 44.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Plus Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Plus Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Plus Therapeutics Inc (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Plus Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 26.68% | $4.36 Million | $16.32 Million | -26.54pp |
| 2024-12-31 | 53.22% | $3.53 Million | $6.63 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $11.39 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $23.99 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $31.61 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $34.61 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $37.70 Million | -- |
| 2006-12-31 | 15.99% | $3.98 Million | $24.87 Million | -11.84pp |
| 2005-12-31 | 27.83% | $7.84 Million | $28.17 Million | -13.71pp |
| 2004-12-31 | 41.54% | $10.58 Million | $25.47 Million | +0.78pp |
| 2003-12-31 | 40.76% | $11.45 Million | $28.09 Million | -9.79pp |
| 2002-12-31 | 50.55% | $19.88 Million | $39.32 Million | -21.89pp |
| 2001-12-31 | 72.44% | $31.25 Million | $43.14 Million | +1.63pp |
| 2000-12-31 | 70.80% | $37.01 Million | $52.27 Million | -- |
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric br… Read more